429 related articles for article (PubMed ID: 35227541)
21. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
22. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
Noble SI; Nelson A; Fitzmaurice D; Bekkers MJ; Baillie J; Sivell S; Canham J; Smith JD; Casbard A; Cohen A; Cohen D; Evans J; Fletcher K; Johnson M; Maraveyas A; Prout H; Hood K
Health Technol Assess; 2015 Oct; 19(83):vii-xxiii, 1-93. PubMed ID: 26490434
[TBL] [Abstract][Full Text] [Related]
23. Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis.
Attard LM; Gatt A; Bertoletti L; Delluc A; Riva N
Vasc Health Risk Manag; 2022; 18():793-807. PubMed ID: 36268462
[TBL] [Abstract][Full Text] [Related]
24. Cost-Utility Analysis Comparing Direct Oral Anticoagulant and Low Molecular Weight Heparin Therapies for Secondary Prevention of Cancer-Associated Thrombosis.
Shin YE; Kumar A; Hwang M; Mackey M; Wu WK
Clin Drug Investig; 2022 Dec; 42(12):1075-1083. PubMed ID: 36315349
[TBL] [Abstract][Full Text] [Related]
25. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.
Martins MA; Silva TF; Fernandes CJ
Curr Oncol Rep; 2023 May; 25(5):425-432. PubMed ID: 36928825
[TBL] [Abstract][Full Text] [Related]
26. Risks, diagnosis, and management of recurrent cancer-associated thrombosis (CAT): a narrative review.
Dickson K; Koom-Dadzie K; Brito-Dellan N; Escalante C
Support Care Cancer; 2022 Oct; 30(10):8539-8545. PubMed ID: 35699781
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
28. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
29. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.
Carrier M; Le Gal G; Cho R; Tierney S; Rodger M; Lee AY
J Thromb Haemost; 2009 May; 7(5):760-5. PubMed ID: 19245418
[TBL] [Abstract][Full Text] [Related]
30. Cancer-associated thrombosis and drug-drug interactions of antithrombotic and antineoplastic agents.
Bolek H; Ürün Y
Cancer; 2023 Oct; 129(20):3216-3229. PubMed ID: 37401828
[TBL] [Abstract][Full Text] [Related]
31. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Ferrante N; Otten HM; Cuccurullo F; Rutjes AW
Cochrane Database Syst Rev; 2012 Feb; (2):CD008500. PubMed ID: 22336844
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis.
Wang TF; Carrier M; Carney BJ; Kimpton M; Delluc A
Thromb Res; 2023 Jul; 227():8-16. PubMed ID: 37196605
[TBL] [Abstract][Full Text] [Related]
33. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
[TBL] [Abstract][Full Text] [Related]
34. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
35. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
36. Venous Thromboembolism In Cancer Patients: "From Evidence to Care".
Salgado M; Brozos-Vázquez E; Campos B; González-Villarroel P; Pérez ME; Vázquez-Tuñas ML; Arias D
Clin Appl Thromb Hemost; 2022; 28():10760296221098717. PubMed ID: 35538861
[TBL] [Abstract][Full Text] [Related]
37. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.
Ihaddadene R; Le Gal G; Delluc A; Carrier M
Thromb Res; 2014 Jul; 134(1):93-5. PubMed ID: 24835673
[TBL] [Abstract][Full Text] [Related]
38. Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.
van Es N; Bleker SM; Wilts IT; Porreca E; Di Nisio M
Drugs; 2016 Mar; 76(3):331-41. PubMed ID: 26729187
[TBL] [Abstract][Full Text] [Related]
39. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
[TBL] [Abstract][Full Text] [Related]
40. A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants.
Wee B; Lai J; Khattak Z; Kwok A; Donarelli C; Ho P; Lim HY; Lui B
J Thromb Thrombolysis; 2024 Apr; 57(4):658-667. PubMed ID: 38393675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
